# Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

> **NCT02052310** · PHASE3 · COMPLETED · sponsor: **Kyntra Bio** · enrollment: 1043 (actual)

## Conditions studied

- Anemia in Incident Dialysis Patients

## Interventions

- **DRUG:** Roxadustat
- **DRUG:** Epoetin Alfa

## Key facts

- **NCT ID:** NCT02052310
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-11
- **Primary completion:** 2018-09-21
- **Final completion:** 2018-09-21
- **Target enrollment:** 1043 (ACTUAL)
- **Last updated:** 2021-10-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052310, "Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02052310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*